Subscribe

Stay Informed. Stay Ahead.

Subscribe to receive curated updates, expert insights, and practical education—delivered straight to your inbox.

Get timely coverage on new approvals, case-based discussions, conference highlights, and practical tools for everyday practice in community oncology and hematology.

Subscribe
*
Skip to main content
OncUpdates
  • Conferences
    • ASCO
      • Rapid Reactions
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
  • Videos & Podcasts
    • Challenging Cases
      • Breast Cancer
      • GU Oncology
      • Hematology
      • Lung Cancer
    • New Approvals
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Tox Check
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • GI Oncology
      • GU Oncology
      • Head and Neck Cancers
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Clinical Insights
    • Head & Neck Cancer
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastric/GEJ Cancer
      • Pancreatic Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
      • Multiple Myeloma
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Cell Therapy
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • GU Oncology
    • Hematology
    • Lung Cancer
  • Events
  • Conferences
    • ASCO
      • Rapid Reactions
    • ASCO GU
    • ASCO GI
    • ASH
    • SABCS
    • ESMO
    • WCLC
  • Videos & Podcasts
    • Challenging Cases
      • Breast Cancer
      • GU Oncology
      • Hematology
      • Lung Cancer
    • New Approvals
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Tox Check
      • Breast Cancer
      • GI Oncology
      • GU Oncology
      • Hematology
      • Lung Cancer
    • Treatment Algorithms
      • Breast Cancer
      • Dermatology
      • GI Oncology
      • GU Oncology
      • Head and Neck Cancers
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Clinical Insights
    • Head & Neck Cancer
    • GU Oncology
      • Bladder Cancer
      • RCC
    • GI Oncology
      • Gastric/GEJ Cancer
      • Pancreatic Cancer
    • Breast Cancer
      • Early HR+
      • Metastatic HR+
    • Hematology
      • Polycythemia Vera
      • Multiple Myeloma
    • Lung Cancer
      • SCLC
      • NSCLC
  • Resource Centers
    • Cell Therapy
    • Pancreatic Cancer
    • Metastatic Breast Cancer
  • Articles
    • GI Oncology
    • GU Oncology
    • Hematology
    • Lung Cancer
  • Events

Explore Videos, Articles & More

Gastric/GEJ Cancer

Expert-led insights in gastric and GEJ cancers highlight evolving treatment strategies, including perioperative and advanced disease management. Focus on integrating emerging data into sequencing and personalized clinical decision-making.

Home / Clinical Insights / GI Oncology / Gastric/GEJ Cancer

ASCO GI 2026: HERIZON-GEA-01

Browse all ASCO GI 2026: HERIZON-GEA-01
Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

ASCO GI 2026: HERIZON-GEA-01

Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

ASCO GI 2026: HERIZON-GEA-01

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

Ep. 2: Managing Efficacy and Toxicity With Zanidatamab in HER2-Positive Disease

ASCO GI 2026: HERIZON-GEA-01

Ep. 2: Managing Efficacy and Toxicity With Zanidatamab in HER2-Positive Disease

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

Ep. 1: Zanidatamab Redefines First-Line Therapy in HER2-Positive Upper GI Malignancies

ASCO GI 2026: HERIZON-GEA-01

Ep. 1: Zanidatamab Redefines First-Line Therapy in HER2-Positive Upper GI Malignancies

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Geoffrey Ku, MD, Rutika Mehta, MD, MB, MPH, Manish Shah, MD, Nataliya Uboha, MD, PhD

ASCO GI 2026: MATTERHORN

Browse all ASCO GI 2026: MATTERHORN
Ep. 4: Next-Line Strategies and Practice Insights for Durvalumab in Gastric and GEJ Cancer

ASCO GI 2026: MATTERHORN

Ep. 4: Next-Line Strategies and Practice Insights for Durvalumab in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

Ep. 3: Balancing Therapy Intensity and Patient Tolerability in Gastric and GEJ Cancer

ASCO GI 2026: MATTERHORN

Ep. 3: Balancing Therapy Intensity and Patient Tolerability in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

Ep. 2: Up-Front PD-L1 Testing and Perioperative Immunotherapy in Gastric and GEJ Cancer

ASCO GI 2026: MATTERHORN

Ep. 2: Up-Front PD-L1 Testing and Perioperative Immunotherapy in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

Ep. 1: Clinical Insights on Perioperative Durvalumab in Gastric and GEJ Cancer

ASCO GI 2026: MATTERHORN

Ep. 1: Clinical Insights on Perioperative Durvalumab in Gastric and GEJ Cancer

Rahul Gosain, MD, MBA, Rohit Gosain, MD, Angela Alistar, MD, Steven Maron, MD, MSc, Reetu Mukherji, MD, Raji Shameem, MD

OncUpdates

Empowering oncology professionals with The latest insights, breakthroughs, And expert opinions

Quick Links

  • About Us
  • Upcoming Events
  • Follow on X
  • Follow on LinkedIn
  • Follow on YouTube

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Settings
  • Authors
  • Contact Us

Subscribe to Our Newsletters


Property of SignifyMD LLC, All Rights Reserved 2026 SignifyMD LLC PO Box 512, Brielle, NJ 08730


Oncology Resources | Hematology Support | Community Oncology